Taehyang Lee
Overview
Explore the profile of Taehyang Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
368
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hong J, Cho H, Sa J, Liu X, Ha S, Lee T, et al.
Genome Med
. 2022 Jan;
14(1):1.
PMID: 34986867
Background: A limited number of studies have characterized genomic properties of hepatocellular carcinoma (HCC) patients in response to anti-PD-1 immunotherapy. Methods: Herein, we performed comprehensive molecular characterization of immediate (D-42...
2.
Cho J, Sim M, Kim S, Kim K, Lee T, Lee J, et al.
J Cancer Res Ther
. 2021 Sep;
17(4):1047-1051.
PMID: 34528562
Background: The aims of this study were to detect circulating tumor cells (CTCs) at the single-cell level in cerebrospinal fluid (CSF) and to identify intrapatient heterogeneity of CTCs in a...
3.
Kwon M, An M, Klempner S, Lee H, Kim K, Sa J, et al.
Cancer Discov
. 2021 Apr;
11(9):2168-2185.
PMID: 33846173
Sequence alterations in microsatellites and an elevated mutational burden are observed in 20% of gastric cancers and associated with clinical response to anti-PD-1 antibodies. However, 50% of microsatellite instability-high (MSI-H)...
4.
Chao J, Lee J, Kim K, Kang S, Lee T, Kim K, et al.
Front Oncol
. 2020 Mar;
10:225.
PMID: 32158697
Intertumoral heterogeneity among actionable biomarkers including and has been observed to occur under therapeutic pressure in advanced gastric cancer. However, baseline intratumoral heterogeneity at diagnosis is understudied and may impact...
5.
Lee J, Kim S, Kim K, Lee H, Kozarewa I, Mortimer P, et al.
Cancer Discov
. 2019 Jul;
9(10):1388-1405.
PMID: 31315834
The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify patients with metastatic gastric cancer based on clinical sequencing and focused on eight different biomarker...
6.
Lee T, Kim K, Lee J, Park S, Park Y, Lim H, et al.
J Cancer
. 2018 Oct;
9(18):3394-3399.
PMID: 30271501
KRAS mutation has been known as crucial marker for growth and maintenance of pancreatic cancer (PC) and targeting the KRAS is inevitable component for realizing precision medicine to PC. We...
7.
Lee J, Liu Z, Sa J, Shin S, Wang J, Bordyuh M, et al.
Nat Genet
. 2018 Sep;
50(10):1399-1411.
PMID: 30262818
Outcomes of anticancer therapy vary dramatically among patients due to diverse genetic and molecular backgrounds, highlighting extensive intertumoral heterogeneity. The fundamental tenet of precision oncology defines molecular characterization of tumors...